Activation of IFN/STAT1 signalling predicts response to chemotherapy in oestrogen receptor-negative breast cancer

British Journal of Cancer

Volumn 114, Issue 2, 2016, Pages 177-187

  Legrier, Marie Emmanuelle ^a   Bièche, Ivan ^b   Gaston, Julie ^a   Beurdeley, Arnaud ^a   Yvonnet, Vanessa ^a   Déas, Olivier ^a   Thuleau, Aurélie ^b   Château Joubert, Sophie ^c   Servely, Jean Luc ^c,d   Vacher, Sophie ^b   Lassalle, Myriam ^a   Depil, Stéphane ^e   Tucker, Gordon C ^e   Fontaine, Jean Jacques ^c   Poupon, Marie France ^a   Roman Roman, Sergio ^b   Judde, Jean Gabriel ^b   Decaudin, Didier ^b   Cairo, Stefano ^a,f   Marangoni, Elisabetta ^b  

^a XenTech   (France)

^b INSTITUT CURIE   (France)

^c ECOLE NATIONALE VÉTÉRINAIRE D ALFORT   (France)

^d CEMAGREF   (France)

^e INSTITUT DE RECHERCHES SERVIER   (France)

^f UNIVERSITY OF FERRARA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CISPLATIN; GAMMA INTERFERON; STAT1 PROTEIN; ANTIGEN; ANTINEOPLASTIC AGENT; BETA INTERFERON; CARRIER PROTEIN; CASP3 PROTEIN, HUMAN; CASP7 PROTEIN, HUMAN; CASPASE 3; CASPASE 7; CYTOKINE; CYTOSKELETON PROTEIN; ESTROGEN RECEPTOR; IFI27 PROTEIN, HUMAN; IFI44 PROTEIN, HUMAN; IFI6 PROTEIN, HUMAN; IFIT1 PROTEIN, HUMAN; IFIT3 PROTEIN, HUMAN; ISG15 PROTEIN, HUMAN; MEMBRANE PROTEIN; MITOCHONDRIAL PROTEIN; MX1 PROTEIN, HUMAN; MYXOVIRUS RESISTANCE PROTEIN; SIGNAL PEPTIDE; STAT1 PROTEIN, HUMAN; UBIQUITIN;

ANIMAL CELL; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER PATIENT; CONTROLLED STUDY; CYTOKINE RELEASE; DNA DAMAGE; ESTROGEN RECEPTOR NEGATIVE BREAST CANCER; FEMALE; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; INFANT; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; TUMOR XENOGRAFT; ANIMAL; BREAST NEOPLASMS; CANCER TRANSPLANTATION; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; METABOLISM; NUDE MOUSE; PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANIMALS; ANTIGENS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOTTING, WESTERN; BREAST NEOPLASMS; CAPECITABINE; CARRIER PROTEINS; CASPASE 3; CASPASE 7; CISPLATIN; CYTOKINES; CYTOSKELETAL PROTEINS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INTERFERON-BETA; INTERFERON-GAMMA; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MEMBRANE PROTEINS; MICE; MICE, NUDE; MITOCHONDRIAL PROTEINS; MYXOVIRUS RESISTANCE PROTEINS; NEOPLASM TRANSPLANTATION; PHOSPHORYLATION; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, ESTROGEN; SIGNAL TRANSDUCTION; STAT1 TRANSCRIPTION FACTOR; UBIQUITINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84955181012     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2015.398     Document Type: Article

References (44)

1. Andersson BS, Mroue M, Britten RA, Murray D (1994) The role of DNA damage in the resistance of human chronic myeloid leukemia cells to cyclophosphamide analogues. Cancer Res 54(20): 5394-5400.
2. Andre F, Dieci MV, Dubsky P, Sotiriou C, Curigliano G, Denkert C, Loi S (2013) Molecular pathways: involvement of immune pathways in the therapeutic response and outcome in breast cancer. Clin Cancer Res 19(1): 28-33.
3. Balko JM, Cook RS, Vaught DB, Kuba MG, Miller TW, Bhola NE, Sanders ME, Granja-Ingram NM, Smith JJ, Meszoely IM, Salter J, Dowsett M, Stemke-Hale K, Gonzalez-Angulo AM, Mills GB, Pinto JA, Gomez HL, Arteaga CL (2012) Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance. Nat Med 18(7): 1052-1059.
4. Bieche I, Parfait B, Le Doussal V, Olivi M, Rio MC, Lidereau R, Vidaud M (2001) Identification of CGA as a novel estrogen receptor-responsive gene in breast cancer: An outstanding candidate marker to predict the response to endocrine therapy. Cancer Res 61(4): 1652-1658.
5. Boidot R, Vegran F, Soubeyrand MS, Fumoleau P, Coudert B, Lizard-Nacol S (2009) Variations in gene expression and response to neoadjuvant chemotherapy in breast carcinoma. Cancer Invest 27(5): 521-528.
6. Brzostek-Racine S, Gordon C, Van Scoy S, Reich NC (2011) The DNA damage response induces IFN. J Immunol 187(10): 5336-5345.
7. Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL, Pusztai L, Green MC, Arun BK, Giordano SH, Cristofanilli M, Frye DK, Smith TL, Hunt KK, Singletary SE, Sahin AA, Ewer MS, Buchholz TA, Berry D, Hortobagyi GN (2005) Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 23(16): 3676-3685.
8. Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML, Perou CM (2007) The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 13(8): 2329-2334.
9. Cheon H, Holvey-Bates EG, Schoggins JW, Forster S, Hertzog P, Imanaka N, Rice CM, Jackson MW, Junk DJ, Stark GR (2013) IFNbeta-dependent increases in STAT1, STAT2, and IRF9 mediate resistance to viruses and DNA damage. EMBO J 32(20): 2751-2763.
10. Cheon H, Stark GR (2009) Unphosphorylated STAT1 prolongs the expression of interferon-induced immune regulatory genes. Proc Natl Acad Sci USA 106(23): 9373-9378.
11. de Plater L, Lauge A, Guyader C, Poupon MF, Assayag F, de Cremoux P, Vincent-Salomon A, Stoppa-Lyonnet D, Sigal-Zafrani B, Fontaine JJ, Brough R, Lord CJ, Ashworth A, Cottu P, Decaudin D, Marangoni E (2010) Establishment and characterisation of a new breast cancer xenograft obtained from a woman carrying a germline BRCA2 mutation. Br J Cancer 103(8): 1192-1200.
12. Franci C, Zhou J, Jiang Z, Modrusan Z, Good Z, Jackson E, Kouros-Mehr H (2013) Biomarkers of residual disease, disseminated tumor cells, and metastases in the MMTV-PyMT breast cancer model. PLoS One 8(3): e58183.
13. Gonzalez-Angulo AM, Iwamoto T, Liu S, Chen H, Do KA, Hortobagyi GN, Mills GB, Meric-Bernstam F, Symmans WF, Pusztai L (2012) Gene expression, molecular class changes, and pathway analysis after neoadjuvant systemic therapy for breast cancer. Clin Cancer Res 18(4): 1109-1119.
14. Hannemann J, Oosterkamp HM, Bosch CA, Velds A, Wessels LF, Loo C, Rutgers EJ, Rodenhuis S, van de Vijver MJ (2005) Changes in gene expression associated with response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 23(15): 3331-3342.
15. Hidalgo M, Amant F, Biankin AV, Budinska E, Byrne AT, Caldas C, Clarke RB, de Jong S, Jonkers J, Maelandsmo GM, Roman-Roman S, Seoane J, Trusolino L, Villanueva A (2014) Patient-derived xenograft models: An emerging platform for translational cancer research. Cancer Discov 4(9): 998-1013.
16. Hussner J, Ameling S, Hammer E, Herzog S, Steil L, Schwebe M, Niessen J, Schroeder HW, Kroemer HK, Ritter CA, Volker U, Bien S (2012) Regulation of interferon-inducible proteins by doxorubicin via interferon gamma-Janus tyrosine kinase-signal transducer and activator of transcription signaling in tumor cells. Mol Pharmacol 81(5): 679-688.
17. Jechlinger M, Sommer A, Moriggl R, Seither P, Kraut N, Capodiecci P, Donovan M, Cordon-Cardo C, Beug H, Grunert S (2006) Autocrine PDGFR signaling promotes mammary cancer metastasis. J Clin Invest 116(6): 1561-1570.
18. Khodarev NN, Minn AJ, Efimova EV, Darga TE, Labay E, Beckett M, Mauceri HJ, Roizman B, Weichselbaum RR (2007) Signal transducer and activator of transcription 1 regulates both cytotoxic and prosurvival functions in tumor cells. Cancer Res 67(19): 9214-9220.
19. Koike Folgueira MA, Brentani H, Carraro DM, De Camargo Barros Filho M, Hirata Katayama ML, Santana de Abreu AP, Mantovani Barbosa E, De Oliveira CT, Patrao DF, Mota LD, Netto MM, Caldeira JR, Brentani MM (2009) Gene expression profile of residual breast cancer after doxorubicin and cyclophosphamide neoadjuvant chemotherapy. Oncol Rep 22(4): 805-813.
20. Korde LA, Lusa L, McShane L, Lebowitz PF, Lukes L, Camphausen K, Parker JS, Swain SM, Hunter K, Zujewski JA (2010) Gene expression pathway analysis to predict response to neoadjuvant docetaxel and capecitabine for breast cancer. Breast Cancer Res Treat 119(3): 685-699.
21. Kumar A, Commane M, Flickinger TW, Horvath CM, Stark GR (1997) Defective TNF-alpha-induced apoptosis in STAT1-null cells due to low constitutive levels of caspases. Science 278(5343): 1630-1632.
22. Lee SC, Xu X, Lim YW, Iau P, Sukri N, Lim SE, Yap HL, Yeo WL, Tan P, Tan SH, McLeod H, Goh BC (2009) Chemotherapy-induced tumor gene expression changes in human breast cancers. Pharmacogenet Genomics 19(3): 181-192.
23. Levy DE, Darnell JE Jr (2002) Stats: Transcriptional control and biological impact. Nat Rev Mol Cell Biol 3(9): 651-662.
24. Liedtke C, Mazouni C, Hess KR, Andre F, Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B, Green M, Cristofanilli M, Hortobagyi GN, Pusztai L (2008) Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 26(8): 1275-1281.
25. Marangoni E, Lecomte N, Durand L, de Pinieux G, Decaudin D, Chomienne C, Smadja-Joffe F, Poupon MF (2009) CD44 targeting reduces tumour growth and prevents post-chemotherapy relapse of human breast cancers xenografts. Br J Cancer 100(6): 918-922.
26. Marangoni E, Poupon MF (2014) Patient-derived tumour xenografts as models for breast cancer drug development. Curr Opin Oncol 26(6): 556-561.
27. Marangoni E, Vincent-Salomon A, Auger N, Degeorges A, Assayag F, de Cremoux P, de Plater L, Guyader C, De Pinieux G, Judde JG, Rebucci M, Tran-Perennou C, Sastre-Garau X, Sigal-Zafrani B, Delattre O, Dieras V, Poupon MF (2007) A new model of patient tumor-derived breast cancer xenografts for preclinical assays. Clin Cancer Res 13(13): 3989-3998.
28. Mesa RA, Yasothan U, Kirkpatrick P (2012) Ruxolitinib. Nat Rev Drug Discov 11(2): 103-104.
29. Miyake T, Nakayama T, Naoi Y, Yamamoto N, Otani Y, Kim SJ, Shimazu K, Shimomura A, Maruyama N, Tamaki Y, Noguchi S (2012) GSTP1 expression predicts poor pathological complete response to neoadjuvant chemotherapy in ER-negative breast cancer. Cancer Sci 103(5): 913-920.
30. Nalini V, Segu R, Deepa PR, Khetan V, Vasudevan M, Krishnakumar S (2013) Molecular insights on post-chemotherapy retinoblastoma by microarray gene expression analysis. Bioinform Biol Insights 7: 289-306.
31. Pedersen MW, Pedersen N, Damstrup L, Villingshoj M, Sonder SU, Rieneck K, Bovin LF, Spang-Thomsen M, Poulsen HS (2005) Analysis of the epidermal growth factor receptor specific transcriptome: effect of receptor expression level and an activating mutation. J Cell Biochem 96(2): 412-427.
32. Platanias LC (2005) Mechanisms of type-I-and type-II-interferon-mediated signalling. Nat Rev Immunol 5(5): 375-386.
33. Reyal F, Guyader C, Decraene C, Lucchesi C, Auger N, Assayag F, De Plater L, Gentien D, Poupon MF, Cottu P, De Cremoux P, Gestraud P, Vincent-Salomon A, Fontaine JJ, Roman-Roman S, Delattre O, Decaudin D, Marangoni E (2012) Molecular profiling of patient-derived breast cancer xenografts. Breast Cancer Res 14(1): R11.
34. Richardson ME, Siemann DW (1995) DNA damage in cyclophosphamide-resistant tumor cells: The role of glutathione. Cancer Res 55(8): 1691-1695.
35. Romanelli A, Clark A, Assayag F, Chateau-Joubert S, Poupon MF, Servely JL, Fontaine JJ, Liu X, Spooner E, Goodstal S, de Cremoux P, Bieche I, Decaudin D, Marangoni E (2012) Inhibiting aurora kinases reduces tumor growth and suppresses tumor recurrence after chemotherapy in patientderived triple-negative breast cancer xenografts. Mol Cancer Ther 11(12): 2693-2703.
36. Rusinova I, Forster S, Yu S, Kannan A, Masse M, Cumming H, Chapman R, Hertzog PJ (2013) Interferome v2. 0: An updated database of annotated interferon-regulated genes. Nucleic Acids Res 41(Database issue): D1040-D1046.
37. Sistigu A, Yamazaki T, Vacchelli E, Chaba K, Enot DP, Adam J, Vitale I, Goubar A, Baracco EE, Remedios C, Fend L, Hannani D, Aymeric L, Ma Y, Niso-Santano M, Kepp O, Schultze JL, Tuting T, Belardelli F, Bracci L, La Sorsa V, Ziccheddu G, Sestili P, Urbani F, Delorenzi M, Lacroix-Triki M, Quidville V, Conforti R, Spano JP, Pusztai L, Poirier-Colame V, Delaloge S, Penault-Llorca F, Ladoire S, Arnould L, Cyrta J, Dessoliers MC, Eggermont A, Bianchi ME, Pittet M, Engblom C, Pfirschke C, Preville X, Uze G, Schreiber RD, Chow MT, Smyth MJ, Proietti E, Andre F, Kroemer G, Zitvogel L (2014) Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat Med 20(11): 1301-1309.
38. Townsend PA, Cragg MS, Davidson SM, McCormick J, Barry S, Lawrence KM, Knight RA, Hubank M, Chen PL, Latchman DS, Stephanou A (2005) STAT-1 facilitates the ATM activated checkpoint pathway following DNA damage. J Cell Sci 118(Pt 8): 1629-1639.
39. Tozlu S, Girault I, Vacher S, Vendrell J, Andrieu C, Spyratos F, Cohen P, Lidereau R, Bieche I (2006) Identification of novel genes that co-cluster with estrogen receptor alpha in breast tumor biopsy specimens, using a large-scale real-time reverse transcription-PCR approach. Endocr Relat Cancer 13(4): 1109-1120.
40. Tsai MH, Cook JA, Chandramouli GV, DeGraff W, Yan H, Zhao S, Coleman CN, Mitchell JB, Chuang EY (2007) Gene expression profiling of breast, prostate, and glioma cells following single versus fractionated doses of radiation. Cancer Res 67(8): 3845-3852.
41. von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA, Gerber B, Eiermann W, Hilfrich J, Huober J, Jackisch C, Kaufmann M, Konecny GE, Denkert C, Nekljudova V, Mehta K, Loibl S (2012) Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 30(15): 1796-1804.
42. Xu H, Xian J, Vire E, McKinney S, Wei V, Wong J, Tong R, Kouzarides T, Caldas C, Aparicio S (2014) Up-regulation of the interferon-related genes in BRCA2 knockout epithelial cells. J Pathol 234(3): 386-397.
43. Yang J, Stark GR (2008) Roles of unphosphorylated STATs in signaling. Cell Res 18(4): 443-451.
44. Zhang X, Shan P, Alam J, Fu XY, Lee PJ (2005) Carbon monoxide differentially modulates STAT1 and STAT3 and inhibits apoptosis via a phosphatidylinositol 3-kinase/Akt and p38 kinase-dependent STAT3 pathway during anoxia-reoxygenation injury. J Biol Chem 280(10): 8714-8721.